# Targeting the gut to heal the skin: probiotic supplementation reduces wound infection risk and clinical burden in critically ill patients—a systematic review and meta-analysis

**Authors:** Yu Peng, Hao Yan, Bowen Shi, Lingyun Lv, Yu Jiang, He Fang, Bing Ma

PMC · DOI: 10.3389/fnut.2026.1778903 · Frontiers in Nutrition · 2026-02-13

## TL;DR

Probiotics may help reduce wound infections and hospital stays in critically ill patients, especially those with burns, according to a review of clinical trials.

## Contribution

This study provides moderate-certainty evidence that probiotics reduce wound infection risk and clinical burden in ICU patients.

## Key findings

- Probiotic supplementation reduced wound infection risk by 48% in critically ill patients.
- Hospital length of stay decreased by 5.24 days with probiotic use.
- Burn patients showed the most significant benefit in wound infection prevention.

## Abstract

To systematically evaluate the impact of probiotic supplementation on wound-specific and systemic clinical outcomes in critically ill patients.

We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) according to PRISMA guidelines. A comprehensive search of six databases was performed up to December 31, 2025. We included RCTs of probiotic/synbiotic interventions in adult ICU patients reporting wound-related outcomes. Study quality and evidence certainty were assessed using Cochrane RoB 2.0 and GRADE frameworks. Data were pooled using random-effects models.

Nineteen RCTs involving 1,384 patients were included. Probiotic supplementation significantly reduced the risk of wound infection (RR = 0.52, 95% CI: 0.38–0.71), with the most pronounced benefit observed in burn patients. It also significantly reduced hospital length of stay (MD = −5.24 days, 95% CI: −8.73 to −1.75) and the duration of antibiotic use (SMD = −0.18, 95% CI: −0.25 to −0.11), and the duration of mechanical ventilation (SMD = −0.90, 95% CI: −1.20 to −0.60). Probiotics were associated with reduced systemic inflammation (CRP SMD = −0.73, 95% CI: −1.15 to −0.32) and improved intestinal barrier function (RR = 1.63, 95% CI: 1.28–2.08). However, no significant effect was found on wound healing time (MD = −5.60 days, 95% CI: −23.09 to 11.88). While overall mortality was not significantly reduced (RR = 0.75, 95% CI: 0.56–1.01, p = 0.06), a significant benefit was observed in severely ill patients (APACHE II > 20). Sensitivity analyses confirmed the robustness of the primary findings.

Moderate-certainty evidence indicates that probiotic supplementation may serve as a beneficial adjunct in critical care, primarily for preventing wound infections and reducing hospital stay and mechanical ventilation duration, with particular efficacy in burn patients. Its effect on accelerating wound healing remains inconclusive. Future research should focus on standardizing interventions and evaluating long-term outcomes.

https://www.crd.york.ac.uk/PROSPERO/view/CRD420251276093, identifier CRD420251276093.

## Linked entities

- **Diseases:** burns (MONDO:0043519)

## Full-text entities

- **Genes:** IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, ALB (albumin) [NCBI Gene 213] {aka FDAHT, HSA, PRO0883, PRO0903, PRO1341}, DAO (D-amino acid oxidase) [NCBI Gene 1610] {aka DAAO, DAMOX, OXDA}, AOC1 (amine oxidase copper containing 1) [NCBI Gene 26] {aka ABP, ABP1, DAO, DAO1, KAO, KDAO}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, HP (haptoglobin) [NCBI Gene 3240] {aka HP2ALPHA2, HPA1S}, CALCA (calcitonin related polypeptide alpha) [NCBI Gene 796] {aka CALC1, CGRP, CGRP-I, CGRP-alpha, CGRP1, CT}
- **Diseases:** APACHE II (MESH:C537730), mortality (MESH:D003643), Anastomotic leak (MESH:D057868), Wound Infection"[MeSH (MESH:D014946), endocrine dysfunction (MESH:D004700), bacteremia (MESH:D016470), immune (MESH:D007154), Infection (MESH:D007239), dysfunction (MESH:D006331), burn infection (MESH:D010302), Gram-negative infections (MESH:D016905), SSI (MESH:D013530), abdominal wounds (MESH:D000007), infectious (MESH:D003141), sepsis (MESH:D018805), septic shock (MESH:D012772), Critical Illness (MESH:D016638), Inflammatory (MESH:D007249), Burn wounds (MESH:D014947), multi (MESH:D015161), edema (MESH:D004487), neutropenic (MESH:D044504), TBI (MESH:D000070642), ICU (MESH:C000657744), endothelial dysfunction (MESH:D014652), Systemic Inflammatory Response Syndrome (MESH:D018746), diarrhea (MESH:D003967), hypoxia (MESH:D000860), Burn (MESH:D002056)
- **Chemicals:** silver sulfadiazine (MESH:D012837), resistant starch (MESH:D000084922), LPS (MESH:D008070), mannitol (MESH:D008353), prebiotics (MESH:D056692), beta-glucan (MESH:D047071), maltodextrin (MESH:C008315), pectin (MESH:D010368), lactulose (MESH:D007792), inulin (MESH:D007444)
- **Species:** Homo sapiens (human, species) [taxon 9606], Bifidobacterium (genus) [taxon 1678], Bacteria Latreille et al. 1825 (Bacteria stick insect, genus) [taxon 629395], Saccharomyces cerevisiae (baker's yeast, species) [taxon 4932], Lacticaseibacillus rhamnosus GG (strain) [taxon 568703], Saccharomyces boulardii [taxon 252598], Pseudomonas aeruginosa (species) [taxon 287]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12946089/full.md

## Figures

12 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12946089/full.md

## References

70 references — full list in the complete paper: https://tomesphere.com/paper/PMC12946089/full.md

---
Source: https://tomesphere.com/paper/PMC12946089